<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422017000100013</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Seguridad Cardiovascular de los Antidiabéticos Orales]]></article-title>
<article-title xml:lang="en"><![CDATA[Cardiovascular Safety of Oral Antidiabetics]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chaves Solano]]></surname>
<given-names><![CDATA[Luis Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bolaños Rodríguez]]></surname>
<given-names><![CDATA[Hernán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas Servicio de Emergencias Hospital Clínica Bíblica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Profesor Universitario en la Universidad Internacional de las Américas Clínica UNIBE Hospital la Católica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>19</volume>
<numero>1-2</numero>
<fpage>13</fpage>
<lpage>17</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422017000100013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422017000100013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422017000100013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La Diabetes Mellitus tipo 2 (DM-2) es un equivalente de riesgo cardiovascular. Existe una gran variedad de fármacos para el control de la glicemia en los pacientes con DM-2, los cuales tienen diferencias en su perfil cardiovascular, unos han demostrado un beneficio en la reducción de riesgo de eventos cardiovasculares, otros tienen un efecto neutro, y en el caso de otros fármacos como las sulfonilureas y las tiazolinedionas existe dudas sobre su seguridad cardiovascular. Sien do DM-2 un equivalente de riesgo coronario, es fundamental tomar en cuenta el perfil de riesgo cardiovascular de estos medicamentos a la hora de iniciar alguna de estas drogas y no solo su eficacia para controlar los niveles de glicemia. El objetivo de esta revisión es comentar sobre los estudios más recientes que evalúan el riesgo cardiovascular con el uso de los distintos antidiabéticos orales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cardiovascular Safety of Oral Antidiabetics Diabetes Mellitus type 2 (DM-2) is an equivalent of cardiovascular risk. There is a wide variety of drugs for the glycemic control in patients with DM-2, which have differences in their cardiovascular profile, some have shown a benefit in reducing the risk of cardiovascular events, others have a neutral effect, and in the case of other drugs such as sulfonylurea and thiazolidinedione, there are doubts about their cardiovascular safety. Being DM-2 an equivalent of coronary risk, it is essential to consider the cardiovascular risk profile of these medicines when starting any of these drugs and not only their effectiveness in controlling glycaemia levels. The objective of this review is to comment on the most recent studies evaluating cardiovascular risk with the use of different oral antidiabetics.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[riesgo cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[glicemia]]></kwd>
<kwd lng="es"><![CDATA[antidiabético]]></kwd>
<kwd lng="en"><![CDATA[diabetes mellitus type 2]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular risk]]></kwd>
<kwd lng="en"><![CDATA[glycemia]]></kwd>
<kwd lng="en"><![CDATA[antidiabetic]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[McGill]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes and Cardiovascular Risk Factors: The Framingham Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1979</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stamle]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes and other risk factos, and 12 yr cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1993</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>434</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haffner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality from Coronary Heart Desease in Subjects with Type 2 Diabetes and in non Diabetic Subjects with and without prior Myocardial Infarction]]></article-title>
<source><![CDATA[NEJM]]></source>
<year></year>
<volume>339</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>229-33</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment on High Cholesterol in Adults (NCEP-ATP)</collab>
<article-title xml:lang=""><![CDATA[Third Report of The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment on High Cholesterol in Adults (NCEP-ATP III)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>3143</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care on Diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Canadian Diabetes Association</collab>
<source><![CDATA[Canadian Journal of Diabetes]]></source>
<year>2013</year>
<volume>37</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>UK Propspective Diabetes Study(UKPDS)</collab>
<article-title xml:lang=""><![CDATA[Intensive blod-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>837-53</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kooy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2009</year>
<volume>169</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>616-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lammana]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2011</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>221-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>The ADVANCE Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes]]></article-title>
<source><![CDATA[N Eng J Med Jun]]></source>
<year>2008</year>
<volume>12</volume>
<numero>358</numero>
<issue>358</issue>
<page-range>24</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shoback]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Greenspan´s Basic and Clincal Endocrinology]]></source>
<year>2011</year>
<edition>9</edition>
<publisher-name><![CDATA[McGraw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riddle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modern Sulphonylureas:Dangerous or Wrongly Accused]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<page-range>629-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roumi]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparative effectiveness of sulfonylureas and metformin on cardiovascular events on type 2 diabetes mellitus: a cohort study]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Suissa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<page-range>706-14</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Danchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[French Registry of Acute ST-Elevation and Non STElevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2010</year>
<volume>95</volume>
<page-range>4993-5002</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From de triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2009</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>773-95</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Irons]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2006</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>168-81</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wosky]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>2457-71</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dormandy]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Charbonnel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Eckland]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>1279-89</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzone]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2006</year>
<volume>296</volume>
<page-range>2572-81</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wolski]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2008</year>
<volume>299</volume>
<page-range>1561-73</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cariou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Staels]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DPP-4 inhibitors in the treatment of type 2 diabetes]]></article-title>
<source><![CDATA[Biochemical Pharmacology]]></source>
<year>2012</year>
<volume>83</volume>
<page-range>823-32</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scirica]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabeets Mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>369</volume>
<page-range>1317-26</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[William]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alogliptine after Acute Coronary Syndrome in Patients with Type 2 Diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2013</year>
<volume>369</volume>
<page-range>1327-35</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>232-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filion]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Suissa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DPP-4 Inhibitors and Heart Failure: Some Reassurance, some Uncertainty]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>735-27</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<source><![CDATA[DeSantis A. Sodium -glucose co-transporter 2 inhibitors for the treatment of type 2 diabetes mellitus]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zinman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year></year>
<volume>2915</volume>
<numero>373</numero>
<issue>373</issue>
<page-range>2117-28</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jodar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características y tipos de agonistas del receptor de GLP-1. Una oportunidad más para la individualización terapéutica]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2014</year>
<volume>143</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>12-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>311-22</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>1834-44</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lixisenatide in Patients with Type 2 Diabetes and Coronary Syndrome]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>2247-57</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dungan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[DeSantis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucagon-Like Peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Up to date]]></source>
<year>2016</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
